OGT and metabolic disease: Hyperglycemia is only one aspect of metabolic disease, so a more in-depth study of OGT-CSC pathway is needed using in vivo models that incorporate stable knockdown OGT/TNBC lines and/or OGT inhibitors with enhanced in vivo activity [72, 73].